Charles W. Newton - 16 Mar 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Financial Officer
Signature
/s/ Heather Turner, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
16 Mar 2022
Transactions value $
$0
Form type
4
Filing time
18 Mar 2022, 16:09:10 UTC
Previous filing
16 Jun 2021
Next filing
06 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +500K $0.00 500K 16 Mar 2022 Common Stock 500K $5.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.